Publications
45
Citations
256
Est. group size
~6
Recurring co-author estimate
Active years
8
Publishing since 2019
Srishti Chakravorty works in cancer immunology, focusing on how cancer treatments such as antibody-drug conjugates and immune checkpoint blocking antibodies affect the tumor microenvironment (the mix of cells surrounding a tumor) and the immune system's response to cancer. Recent work includes studying how a cytotoxic antibody-drug conjugate reshapes immune cells within tumors, and characterizing a new antibody therapy (vibostolimab) that targets the TIGIT immune checkpoint. The available record consists mainly of a single 2025 research article and its associated supplementary materials, alongside one other 2025 paper.
Publication counts were low or absent from 2017-2021, rose notably in 2023, dipped in 2024, and show a large spike in 2025-2026 driven largely by supplementary materials tied to a single primary article, making the overall trend difficult to characterize as steady or growing based on substantive publications alone.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Supplementary Figure 2 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
2026
- Supplementary Table 2 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
2026
- Supplementary Figure 9 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
2026
- Supplementary Figure 7 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
2026
- Data from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
2026
- Supplementary Table 1 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
2026
- Supplementary Figure 10 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
2026
- Supplementary Figure 11 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
2026
- Supplementary Figure 1 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
2026
- Supplementary Figure 8 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
2026
- Supplementary Figure 4 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
2026
- Supplementary Figure 3 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
2026
- Supplementary Figure 6 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
2026
- Supplementary Figure 5 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
2026
- Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
Molecular Cancer Therapeutics · 2025
- Cancer Research×2
- bioRxiv (Cold Spring Harbor Laboratory)×2
- The Journal of Immunology×2
- Frontiers in Immunology×1
- Journal of Virology×1
- Leona W. Ayers
Medicine · The Ohio State University
- Matthew R. Olson
Medicine · Purdue University West Lafayette
- Luopin Wang
Medicine · Purdue University West Lafayette
- Jana M. Cable
Medicine · The Ohio State University
- Toby Maurer
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile